Rochester,NY 8/14/2009 12:28:48 AM
Hemispherx BioPharma, Inc.,HEB-Second Quarter 2009 Financial Results
Hemispherx BioPharma, Inc
Hemispherx Biopharma, Inc. declared its financial results for the three months ended June 30, 2009. The net loss (including non-cash expenses) for the fiscal quarter was approximately $3,870,000 or $0.04 per share compared to a loss of approximately $2,802,000 or $0.04 per share for the same period in 2008.
http://StockEinstein.com offers free daily stock alerts on companies ready to run. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
The increase in loss was primarily due to the following 1) non-cash R&D expenses related to employee compensation, 2) bonus awards to certain executives for achieving certain 2008 corporate goals and 3) expenses related to preparing the New Brunswick facility in anticipation of expanded production of Ampligen(r) and Alferon N Injection(r). Cash used in operating activities for the first 6 months was reduced 21.8% relative to the same period in year 2008.
StockEinstein.com has a dedicated team uncovering stocks ready to break and run. We apply time tested criteria and when one of these stocks meets or exceeds our benchmarks, our subscribers are immediately notified directly to their in-box.
This is a free service available only to our subscribers. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
During 2009 our alerts have resulted in an average price gain of 80%+.
Disclaimer: Full disclaimer at http://StockEinstein.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither StockEinstein, nor any of its affiliates are registered investment advisors or broker dealers.
